Bose Muthu Ramalingam, Hans J Oh, John D Sears, Chun-Hsing Chen, Anand Vala, Shubin Liu, Kacey M Talbot, Mohammed Anwar Hossain, Peter J Brown, Scott Houliston, Julia Garcia Perez, Fengling Li, Meareg G Amare, Peter Halfmann, Jessica L Smith, Alec J Hirsch, Cheryl H Arrowsmith, Levon Halabelian, Ava Vargason, Rafael M Couñago, Jamie J Arnold, Craig E Cameron, Nathaniel J Moorman, Mark T Heise, Timothy M Willson
{"title":"Enantioselective Chemical Probe for Chikungunya nsP2 Helicase with Antialphaviral Activity.","authors":"Bose Muthu Ramalingam, Hans J Oh, John D Sears, Chun-Hsing Chen, Anand Vala, Shubin Liu, Kacey M Talbot, Mohammed Anwar Hossain, Peter J Brown, Scott Houliston, Julia Garcia Perez, Fengling Li, Meareg G Amare, Peter Halfmann, Jessica L Smith, Alec J Hirsch, Cheryl H Arrowsmith, Levon Halabelian, Ava Vargason, Rafael M Couñago, Jamie J Arnold, Craig E Cameron, Nathaniel J Moorman, Mark T Heise, Timothy M Willson","doi":"10.1021/acsinfecdis.5c00351","DOIUrl":null,"url":null,"abstract":"<p><p>Chikungunya virus (CHIKV) replication relies on the multifunctional nsP2 protein, making it an attractive target for antiviral drug discovery. Here, we report the resolution of oxaspiropiperidine <b>1</b>, a first-in-class inhibitor of the CHIKV nsP2 RNA helicase (nsP2hel), into its constitutive enantiomers and characterization of their antiviral activity. The enantiomer (<i>R</i>)-<b>1</b> exhibited potent inhibition of viral replication, nsP2hel ATPase activity, and dsRNA unwinding, while the (<i>S</i>)-<b>1</b> enantiomer was >100-fold less active. The (<i>R</i>)-<b>1</b> enantiomer also demonstrated a high selectivity for CHIKV over other RNA viruses and for nsP2hel over other RNA helicases. Direct binding of (<i>R</i>)-<b>1</b> to the nsP2hel protein was confirmed by <sup>19</sup>F NMR. Biophysical and structural studies revealed conformational polymorphism in the spirocyclic scaffold of (<i>R</i>)-<b>1</b>, suggesting a potential role of thermal mobility of the ligand in allosteric inhibition of nsP2hel. Collectively, these findings designate (<i>R</i>)-<b>1</b> (RA-NSP2-<b>1</b>) as a high-quality chemical probe and (<i>S</i>)-<b>1</b> (RA-NSP2-<b>1</b>N) as a negative control for probing the biology of alphavirus RNA helicases.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsinfecdis.5c00351","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Chikungunya virus (CHIKV) replication relies on the multifunctional nsP2 protein, making it an attractive target for antiviral drug discovery. Here, we report the resolution of oxaspiropiperidine 1, a first-in-class inhibitor of the CHIKV nsP2 RNA helicase (nsP2hel), into its constitutive enantiomers and characterization of their antiviral activity. The enantiomer (R)-1 exhibited potent inhibition of viral replication, nsP2hel ATPase activity, and dsRNA unwinding, while the (S)-1 enantiomer was >100-fold less active. The (R)-1 enantiomer also demonstrated a high selectivity for CHIKV over other RNA viruses and for nsP2hel over other RNA helicases. Direct binding of (R)-1 to the nsP2hel protein was confirmed by 19F NMR. Biophysical and structural studies revealed conformational polymorphism in the spirocyclic scaffold of (R)-1, suggesting a potential role of thermal mobility of the ligand in allosteric inhibition of nsP2hel. Collectively, these findings designate (R)-1 (RA-NSP2-1) as a high-quality chemical probe and (S)-1 (RA-NSP2-1N) as a negative control for probing the biology of alphavirus RNA helicases.
期刊介绍:
ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to:
* Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials.
* Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets.
* Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance.
* Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents.
* Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota.
* Small molecule vaccine adjuvants for infectious disease.
* Viral and bacterial biochemistry and molecular biology.